Marshall Wace’s Bicycle Therapeutics BCYC Stock Holding History

Marshall Wace’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.38M	Buy	797,940 +420,605	+111%	+$1.93M	﹤0.01%	1571
2026 Q1	$1.75M	Buy	377,335 +338,540	+873%	+$1.93M	﹤0.01%	1860
2025 Q4	$275K	Buy	+38,795	New	+$286K	﹤0.01%	2486
2024 Q4	–	Sell	-330,258	Closed	-$7.47M	–	2584
2024 Q3	$7.47M	Buy	330,258 +241,271	+271%	+$5.57M	0.01%	864
2024 Q2	$1.8M	Buy	+88,987	New	+$2.01M	﹤0.01%	1427
2023 Q3	–	Sell	-9,271	Closed	-$237K	–	2197
2023 Q2	$237K	Sell	9,271 -67,378	-88%	-$1.56M	﹤0.01%	2202
2023 Q1	$1.63M	Buy	76,649 +67,378	+727%	+$1.69M	﹤0.01%	1566
2022 Q4	$274K	Hold	9,271	–	–	﹤0.01%	2593
2022 Q3	$216K	Sell	9,271 -70,852	-88%	-$1.69M	﹤0.01%	3062
2022 Q2	$1.34M	Buy	80,123 +69,504	+655%	+$1.47M	﹤0.01%	2266
2022 Q1	$466K	Sell	10,619 -39,779	-79%	-$1.86M	﹤0.01%	2809
2021 Q4	$3.07M	Buy	50,398 +42,704	+555%	+$2.36M	0.01%	1753
2021 Q3	$320K	Hold	7,694	–	–	﹤0.01%	2620
2021 Q2	$234K	Sell	7,694 -14,223	-65%	-$430K	﹤0.01%	2408
2021 Q1	$655K	Buy	+21,917	New	+$565K	﹤0.01%	1834

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's BCYC Position: Q2 2026 in Review

Marshall Wace increased its Bicycle Therapeutics (BCYC) stake by 111% in Q2 2026, buying an estimated $1.93M and bringing the position to 797,940 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1571.

Marshall Wace first reported a position in BCYC in Q1 2021 and has held it in 15 quarters since. The position peaked at $7.47M in Q3 2024. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Marshall Wace held 797,940 shares of Bicycle Therapeutics worth $3.38M as of Q2 2026.
Marshall Wace bought 420,605 Bicycle Therapeutics shares in Q2 2026, an estimated $1.93M.
Bicycle Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1571 holding.
Marshall Wace first reported a position in Bicycle Therapeutics in Q1 2021 and has held it in 15 quarters since.
Marshall Wace's Bicycle Therapeutics position peaked at $7.47M in Q3 2024.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.